Renal cell carcinoma · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-CASCADE-VHL-FDR-POSITIVE-TESTING`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-RCC`
Sources	`SRC-ASCO-ACMG-LYNCH-2014` `SRC-NCCN-KIDNEY-2025`

Notes

STUB — v0.2-B cascade-testing pilot 2026-05-19 (VHL FDR-positive). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode. Childhood-onset surveillance dependency motivates testing from age 1. Companion alternative track — IND-CASCADE-VHL-FDR-POSITIVE-SURVEILLANCE.

Used By

Indication

IND-CASCADE-VHL-FDR-POSITIVE-SURVEILLANCE - IND-CASCADE-VHL-FDR-POSITIVE-SURVEILLANCE

Red flag

RF-CASCADE-VHL-FDR-POSITIVE - A first-degree relative of the patient (parent, sibling, or child) has a documented posit...